Literature DB >> 16536669

Evaluating smokers' reactions to advertising for new lower nicotine quest cigarettes.

William G Shadel1, Caryn Lerman, Joseph Cappella, Andrew A Strasser, Angela Pinto, Robert Hornik.   

Abstract

Quest cigarettes are a relatively new (2003) product that has been marketed as a way for smokers to gradually reduce the nicotine they receive from cigarettes in order to, according to marketing materials, become nicotine free. However, despite lower levels of nicotine, Quest cigarettes do not have reduced tar levels and, thus, still pose health hazards. This study evaluated beliefs about Quest cigarettes following exposure to a single print advertisement among 200 regular smokers who had never heard of the brand itself. Descriptively, smokers made several specific false inferences about Quest cigarettes after exposure (i.e., lower in tar, healthier, less likely to cause cancer). Two individual-differences variables, need for cognition and perceived vulnerability, moderated smokers' health beliefs about Quest cigarettes.

Entities:  

Mesh:

Year:  2006        PMID: 16536669     DOI: 10.1037/0893-164X.20.1.80

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  21 in total

1.  Impact of corrective health information on consumers' perceptions of "reduced exposure" tobacco products.

Authors:  Lois Biener; Karen Bogen; Gregory Connolly
Journal:  Tob Control       Date:  2007-10       Impact factor: 7.552

2.  Educating smokers about their cigarettes and nicotine medications.

Authors:  Maansi Bansal-Travers; K Michael Cummings; Andrew Hyland; Anthony Brown; Paula Celestino
Journal:  Health Educ Res       Date:  2010-01-11

3.  Using eye-tracking to examine how embedding risk corrective statements improves cigarette risk beliefs: Implications for tobacco regulatory policy.

Authors:  Kirsten Lochbuehler; Kathy Z Tang; Valentina Souprountchouk; Dana Campetti; Joseph N Cappella; Lynn T Kozlowski; Andrew A Strasser
Journal:  Drug Alcohol Depend       Date:  2016-05-02       Impact factor: 4.492

4.  Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks.

Authors:  Lauren R Pacek; F Joseph McClernon; Rachel L Denlinger-Apte; Melissa Mercincavage; Andrew A Strasser; Sarah S Dermody; Ryan Vandrey; Tracy T Smith; Natalie Nardone; Dorothy K Hatsukami; Joseph S Koopmeiners; Rachel V Kozink; Eric C Donny
Journal:  Tob Control       Date:  2017-07-22       Impact factor: 7.552

5.  What do cigarette pack colors communicate to smokers in the U.S.?

Authors:  Maansi Bansal-Travers; Richard O'Connor; Brian V Fix; K Michael Cummings
Journal:  Am J Prev Med       Date:  2011-06       Impact factor: 5.043

6.  Reduced nicotine content cigarette advertising: How false beliefs and subjective ratings affect smoking behavior.

Authors:  Melissa Mercincavage; Megan L Saddleson; Emily Gup; Angela Halstead; Darren Mays; Andrew A Strasser
Journal:  Drug Alcohol Depend       Date:  2017-02-03       Impact factor: 4.492

7.  Graphic warning labels in cigarette advertisements: recall and viewing patterns.

Authors:  Andrew A Strasser; Kathy Z Tang; Daniel Romer; Christopher Jepson; Joseph N Cappella
Journal:  Am J Prev Med       Date:  2012-07       Impact factor: 5.043

8.  Nicotine vaccines: will smokers take a shot at quitting?

Authors:  Amy E Leader; Caryn Lerman; Joseph N Cappella
Journal:  Nicotine Tob Res       Date:  2010-02-25       Impact factor: 4.244

Review 9.  Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods.

Authors:  Vaughan W Rees; Jennifer M Kreslake; K Michael Cummings; Richard J O'Connor; Dorothy K Hatsukami; Mark Parascandola; Peter G Shields; Gregory N Connolly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  PREP advertisement features affect smokers' beliefs regarding potential harm.

Authors:  A A Strasser; K Z Tang; M D Tuller; J N Cappella
Journal:  Tob Control       Date:  2008-09       Impact factor: 7.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.